Login to Your Account


Amyloid aggregation may be a feature, not a bug, of the protein’s function. A bug-catching feature.

more »

Our Habitat for All Things Science
Efficacy comes to phase I cancer trials

Findings that precision medicine benefits patients even in phase I trials, and patients treated with Keytruda (pembrolizumab, Merck & Co. Inc.) had a three-year survival rate of about 40 percent, were among the highlights of the sprawling treasure trove that is the American Society of Clinical Oncology's (ASCO) annual meeting abstracts. Abstracts for the 2016 annual meeting, which will be held in Chicago June 3-7, were publicly released yesterday.



Partners in Focus